So "GLP-3" in community usage typically means "triple agonist" or "third-generation GLP-class peptide." It does not mean a fourth type of receptor beyond GLP-1 and GLP-2
More energy Has my b levels on point Perfect for energy and overall feeling great
Assuming it follows similar patterns, retatrutide most likely wont be recommended for people with : A history of pancreatitis Thyroid cancer or multiple endocrine neoplasia syndrome Severe kidney problems Severe liver issues Worried about side effects
The inclusion of oral GLP-1s at $149/month could make these medications even more accessible for patients who prefer a pill over injections
[DOI] [PMC free article] [PubMed] [Google Scholar] 172.Xu L.L., Zhao B., Sun S.L., Yu S.F., Wang Y.M., Ji R., Yang Z.T., Ma L., Yao Y., Chen Y., et al
Jillian Gilchrest, D-West Hartford, said of the proposal